Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery
Open Access
- 5 November 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 4 (2) , 185-192
Abstract
Disease monitoring in nonalcoholic steatohepatitis (NASH) is limited by absence of noninvasive biomarkers of disease regression or progression. We aimed to examine the role of multiparametric three‐dimensional magnetic resonance elastography (3D‐MRE) and magnetic resonance imaging proton density fat fraction (MRI‐PDFF) in the detection of NASH regression after interventions. This is a single‐center prospective clinical trial of 40 patients who underwent bariatric surgery. Imaging and liver biopsies were obtained at baseline and 1 year after surgery. The imaging protocol consisted of multifrequency 3D‐MRE to determine the shear stiffness at 60 Hz and damping ratio at 40 Hz, and MRI‐PDFF to measure the fat fraction. A logistic regression model including these three parameters was previously found to correlate with NASH. We assessed the model performance in the detection of NASH resolution after surgery by comparing the image‐predicted change in NAFLD activity score (delta NAS) to the histologic changes. A total of 38 patients (median age 43, 87% female, 30 of 38 with NAS ≥ 1, and 13 of 38 with NASH) had complete data at 1 year. The NAS decreased in all subjects with NAS ≥ 1 at index biopsy, and NASH resolved in all 13. There was a strong correlation between the predicted delta NAS by imaging and the delta NAS by histology (r = 0.73, P < 0.001). The strength of correlation between histology and the predicted delta NAS using single conventional parameters, such as the fat fraction by MRI‐PDFF or shear stiffness at 60 Hz by MRE, was r = 0.69 (P < 0.001) and r = 0.43 (P = 0.009), respectively. Conclusion: Multiparametric 3D‐MRE and MRI‐PDFF can detect histologic changes of NASH resolution after bariatric surgery. Studies in a nonbariatric setting are needed to confirm the performance as a composite noninvasive biomarker for longitudinal NASH monitoring.Keywords
Funding Information
- American College of Gastroenterology (Junior Faculty Development Grant)
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK115594, P30DK084567)
- National Institute on Alcohol Abuse and Alcoholism (AA021171, AA26887)
This publication has 20 references indexed in Scilit:
- The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric SurgeryHepatology, 2020
- Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastographyEuropean Radiology, 2019
- Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-upObesity Surgery, 2017
- Distinguishing between Hepatic Inflammation and Fibrosis with MR ElastographyRadiology, 2017
- Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat FractionObesity Surgery, 2017
- Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitisTherapeutic Advances in Gastroenterology, 2016
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015
- Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgeryBMC Medicine, 2014
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005